The study by Ropper et al. showed that plasmid VEGF can effectively alleviate neuropathic symptoms and reduce pain in patients with type 1 and type 2 diabetes, demonstrating the potential for gene therapy to address diabetic complications beyond glycemic control [27]. This evidence concerns the gene VEGFA and type 2 diabetes mellitus.